|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/4439 | (2006.01) |
| C07D 405/14 | (2006.01) | ||
| A61P 3/10 | (2006.01) |
| (11) | Number of the document | 3989972 |
| (13) | Kind of document | T |
| (96) | European patent application number | 20739523.7 |
| Date of filing the European patent application | 2020-06-19 | |
| (97) | Date of publication of the European application | 2022-05-04 |
| (45) | Date of publication and mention of the grant of the patent | 2023-11-08 |
| (46) | Date of publication of the claims translation | 2023-12-27 |
| (86) | Number | PCT/US2020/038617 |
| Date | 2020-06-19 |
| (87) | Number | WO 2020/263695 |
| Date | 2020-12-30 |
| (30) | Number | Date | Country code |
| 201962868117 P | 2019-06-28 | US | |
| 201962904906 P | 2019-09-24 | US |
| (72) |
COATES, David Andrew , US
FIELDS, Todd , US
HO, Joseph Daniel , US
QU, Fucheng , US
|
| (73) |
ELI LILLY AND COMPANY ,
Lilly Corporate Center, Indianapolis, IN 46206-6288,
US
|
| (74) |
Liudmila GERASIMOVIČ,
IĮ "Liudmila Gerasimovič, Patentinis patikėtinis", Vingrių g. 13-42, LT-01141 Vilnius,
LT
|
| (54) | Į gliukagoną panašaus peptido 1 receptoriaus agonistai |
| GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS |
| Payment date | Validity (years) | Amount | |
| 2025-05-20 | 6 | 139.00 EUR |
| 2026-06-19 |